Should a patient with polycythemia vera and a platelet count of 948 ×10⁹/L be started on antiplatelet therapy?

Yes, you need antiplatelet therapy for polycythemia vera with a platelet count of 948 ×10⁹/L

All patients with polycythemia vera should receive low-dose aspirin (81-100 mg daily) for thrombosis prevention, regardless of platelet count, unless there is a clear contraindication such as active bleeding or acquired von Willebrand disease. 1

Rationale for Antiplatelet Therapy in PV

The evidence strongly supports aspirin use in PV to reduce thrombotic complications, which are the leading cause of morbidity and mortality in this disease. The European Collaboration on Low-dose Aspirin in Polycythemia Vera trial demonstrated that aspirin 100 mg daily was effective in preventing thrombotic complications in PV patients, even with elevated platelet counts 1. This represents Level I evidence for aspirin use in PV.

Your platelet count of 948 ×10⁹/L does not contraindicate aspirin therapy. In fact, the guidelines specifically note that aspirin is effective "even in the face of higher-than-normal platelet counts" 1.

Key Considerations for Your Specific Situation

When to Use Aspirin

• Start aspirin immediately at 81-100 mg daily 1, 2
• This applies to all PV patients unless contraindications exist
• The prophylactic use of low-dose aspirin in PV has been established in guidelines 3

When to Withhold or Use Caution with Aspirin

You should avoid or carefully reconsider aspirin only if:

• Extreme thrombocytosis (platelet count ≥1,500 ×10⁹/L): This can cause acquired von Willebrand disease, increasing bleeding risk 2, 4
• Active bleeding or recent major hemorrhage
• Known aspirin allergy or intolerance

Your platelet count of 948 ×10⁹/L is well below the 1,500 ×10⁹/L threshold where bleeding risk becomes a significant concern.

Additional Management Beyond Aspirin

With a platelet count of 948 ×10⁹/L, you also need:

1. Phlebotomy to maintain hematocrit <45% 5, 2

This is the cornerstone of PV management and takes priority even over cytoreduction.

2. Risk Stratification for Cytoreductive Therapy

Your need for cytoreductive therapy (hydroxyurea or interferon) depends on:

• High-risk criteria (requiring cytoreduction):

  • Age ≥60 years, OR
  • Prior thrombosis history 5, 2

• Additional indications for cytoreduction 5:

  • Uncontrolled myeloproliferation (platelet count >400 ×10⁹/L AND WBC >10 ×10⁹/L)
  • Symptomatic splenomegaly
  • Severe disease-related symptoms
  • Poor tolerance to phlebotomy

Your platelet count of 948 ×10⁹/L alone suggests uncontrolled myeloproliferation and may warrant cytoreductive therapy, particularly if your white blood cell count is also elevated.

Common Pitfalls to Avoid

1. Don't withhold aspirin based solely on elevated platelet count unless it exceeds 1,500 ×10⁹/L
2. Don't use aspirin as monotherapy - it must be combined with phlebotomy and potentially cytoreduction
3. Don't assume twice-daily aspirin is necessary - once-daily dosing (81-100 mg) is standard, though some patients with inadequate platelet inhibition may benefit from twice-daily dosing 6

Monitoring

• Monitor for bleeding complications, especially mucocutaneous bleeding
• If platelet count rises above 1,500 ×10⁹/L, consider testing for acquired von Willebrand disease before continuing aspirin
• Serum thromboxane B2 measurement can guide precision dosing if standard aspirin appears inadequate 6

Bottom line: Start aspirin 81-100 mg daily now, ensure hematocrit is maintained <45% with phlebotomy, and discuss cytoreductive therapy with your hematologist based on your age, thrombosis history, and symptom burden.